Skin and Joints Podcast

Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨

Ready to revolutionize your approach to atopic dermatitis?  🤔

Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱

Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment.

Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile.  📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients..

🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢

🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡

Learning Objectives:

1. Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬.
2. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈.
3. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆.
4. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺.
5. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯.

ABOUT DR.MARISSA JOSEPH

Dermatologist, Toronto, ON

Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

Epsode supported by an Independent Medical Educational Grant from Lilly.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🚴‍♀️ Biking and the Battle Against Itch! 🎙️

Live from the charming canals of Amsterdam at the EADV 2024 meeting, we sit down with the ever-energetic Dr. Perla Lansang from Toronto! 

🍁 She's ditched cabs and metros to embrace the Dutch biking culture, even bringing her own bike across the pond! 🚲🌍 From navigating streets with more bikes than people 😲 to packing rain ponchos for unpredictable weather ☔, Dr. Lansang shares her love for the city.

🍽️ She's on a mission to find the best delectable mini Dutch pancakes topped with butter and powdered sugar 🥞✨. And while we couldn't coax the secret behind her infamous kale smoothie 🥬🥤, we dive into something even more exciting.

We explore late breaking fresh new data presented at EADV on nemolizumab, the new therapeutic targeting IL-31 that's set to revolutionize atopic dermatitis treatment! What does this new 56-week data from an interim analysis of the phase III ARCADIA long-term extension study mean for your patients?

🧪🔥 Discover how this game-changing drug offers rapid itch relief—some patients feel better in just days! 😮🧖‍♂️

We'll unpack nemolizumab’s long-term efficacy and safety in atopic dermatitis, discuss the stellar safety profile, and delve into how it is poised to transform patient care by improving sleep 😴 and overall quality of life 🌟.

This episode is packed with laughs 😂, insightful clinical pearls 🩺, and a sprinkle of Dutch delight! 🎧🌷

Learning Objectives:

1. Understand the pivotal role of IL-31 in atopic dermatitis and why nemolizumab's targeting of this cytokine is a breakthrough.
2. Review the design, key findings, and clinical significance of the Arcadia 1 and 2 long-term extension data up to 56 weeks.
3. Discuss the rapid efficacy and excellent safety profile of nemolizumab and its impact on itch relief, clearance and patient adherence.
4. Evaluate the clinical implications of integrating nemolizumab into practice and its potential to transform atopic dermatitis management.

ABOUT  Dr. Perla Lansang, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Perla Lansang is a full-time staff dermatologist and associate professor in the Division of Dermatology, University of Toronto where she is the Division Head of Dermatology at Sunnybrook Health Sciences Centre. She is also cross appointed at the Section of Paediatric Dermatology at the Hospital for Sick Children, and the Division of Obstetric Medicine at Sunnybrook Health Sciences Centre.

She completed her medical school and dermatology residency at the University of the Philippines-Philippine General Hospital. Having done fellowships in paediatric dermatology at The Hospital for Sick Children and in advanced medical dermatology at Sunnybrook Health Sciences Centre, Dr. Lansang’s practice is a mixture of pediatric, adolescent, and adult dermatology, with a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, pregnancy dermatoses, and general medical dermatology. She has a special interest in immune-mediated skin diseases and has extensive clinical and research experience in many areas of immunodermatology.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🎙 Amsterdam Stories, Delta Force  & A Game-Changing Topical for Chronic Hand Eczema

🎉✨ Melinda Knows Best is BACK! 🚀💥

This time, Dr. Gooderham brings us a heavyweight showdown 🥊 between a new topical superhero 🦸‍♀️ and the reigning oral champ 💊 in the battle against Chronic Hand Eczema!  reporting live from the European Academy of Dermatology and Venereology (EADV) Congress in the beautiful city of Amsterdam! 🇳🇱✨

In this special episode, we’re diving into the Delta Force Trial – a bold study comparing topical delgocitinib to oral alitretinoin for chronic hand eczema  💊🧴

👀 Dr. Gooderham spills the beans on impressive results, rapid relief, and how this new treatment is about to change the game for dermatologists and patients alike. 🎉

Oh, and don’t worry, we didn’t forget to ask  about her Amsterdam adventures! 🌍 Did she run into some famous faces at dinner? 🍽️👀 Tune in for the scoop!

💡 Melinda Knows Best will keep you at the cutting edge of CHE breakthroughs. 👩‍⚕️✨

🎯 Learning Objectives:

1. Explore the Delta Force Trial Findings: Understand the significance of the Delta Force trial comparing topical delgocitinib to oral alitretinoin for chronic hand eczema. 🧴💊
2. Evaluate the Efficacy of Topicals vs Orals for chronic hand eczema: Learn about the early onset of symptom relief with delgocitinib, including i reductions in HEXI scores and patient quality of life improvements. ⏱️📉
3. Identify Key Real-World Implications: Discuss how this new topical treatment can shift the landscape for clinicians and patients, offering rapid, safe relief without the headaches (literally!) of oral therapies. 💡
4.  Dive into secondary endpoints, including itch and pain relief, and how this data compares to other major clinical trials in hand eczema treatment. 📊🔬

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🎙️ Skin Joins Podcast Wrap-Up: Sunny Stories & Cool Pools 🌞

We welcome back Dr. Michele Ramien, who graced our podcast last July from the sunny World Congress of Dermatology in Singapore. 🌏 Fast forward, she reflects on dermatology innovation from vibrant city of San Diego! 🌴

Dr. Ramien shares a delightful (and chilly) San Diego story about renting a house wit, a freezing-cold pool, and a group of eager people determined to swim🏊‍♂️❄️

We deep dive into the exciting highlights from the American Academy of Dermatology conference. Dr. Ramien, attending AAD for the first time in a while, reveals fascinating pearls and🩺✨ innovative treatments including the potential for disease remission in young patients, as well as fresh new insights on melasma and post-inflammatory hyperpigmentation in Asian skin 🌟

Dr. Ramien also touches on the importance of adapting treatments for different skin types and the promising future of pediatric dermatology. 👶💡

Learning Objectives:

1. 🌍 Understand the global advancements in dermatology from the AAD conference.
2. 🧴 Learn about innovative treatments for atopic dermatitis, including pediatric applications.
3. 🎨 Explore the management of melasma and post-inflammatory hyperpigmentation in diverse skin types.
4. 🧒 Discover the potential for disease remission in young patients with early and targeted treatments.

Tune in for a blend of personal stories, professional insights, and a sneak peek into the future of dermatological treatments. 📚🔍

Stay tuned, stay informed, and as always, keep your skin happy 🌟🧴

Supported by an IME Grant from Pfizer
 

ABOUT Dr. Michele L. Ramien

Pediatric Dermatologist  |  Calgary

Dr. Michele Ramien is an academic dermatologist based at the Alberta Children’s Hospital, in the foothills of the Rocky Mountains in Calgary, Canada. She has both pediatric and general medical dermatology practices, with a focus on teaching and mentoring the next generations and research interests in eczema management, patient education, and severe cutaneous reactions in children.

Dr. Ramien enjoys volunteer leadership positions as a way to meet colleagues across the country, like-minded and not, who believe that a small group of thoughtful, committed individuals can change and improve dermatology and delivery of care in Canada.  

📻www.skinandjoints.ca

✉️[email protected]

🎙️ More than Skin Deep Insights with Dr. Lauren Lam!🎙️

👩‍⚕️💬 As we get close to wrapping up our coverage of AAD 2024, get ready as we welcome back Dr. Lauren Lam. We dive deep into her recent experience at the AAD in sunny San Diego. 🌞🏖️

Learning Objectives:

1. 🧠 Understand the practical applications of translational medicine in dermatology, particularly in treating chronic skin conditions.
2. 🛠️ Identify key clinical pearls and advancements in dermatology that can be immediately implemented in practice to improve patient care.

What’s on the agenda for this mini-podcast drop?

1. 🌟 San Diego Stories: From bar hopping in a Japanese-themed spot 🌸🍹 to pelican watching at the pier 🦩📸, Lauren shares her unique experiences and the vibrant cultural mix that San Diego offers.
2. 🔍 Translational Medicine Takeaways: Discover how the latest advancements in bench-to-bedside research are transforming dermatological practices. 🧬🩺
3. 💡 Clinical Pearls Galore:

• Hidradenitis Suppurativa Insights: Understand why de-roofing is essential even with biologics 🩹🔬.
• Alopecia Areata Breakthroughs: Learn about the impact of JAK inhibitors 🧑‍🦲➡️🧑‍🦰.
• Pyoderma Gangrenosum Progress: Hear about the promising results of IL-36 inhibitors in treating this challenging condition 💉🌟.

Join us for a lively episode that blends professional insights with personal anecdotes, and don't miss out on the laughter and wisdom Dr. Lam brings to the table 🎧✨

ABOUT Dr. Lauren Lam 

Dermatologist  |  Calgary

Dr. Lauren Lam is a Canadian & American board-certified dermatologist. She is a native Calgarian who completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings. In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

📻www.skinandjoints.ca

✉️[email protected]

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 2🎙️

Description:

In Part 2, dermooncologist Dr. Max Sauder returns to delve deeper into the CASMO algorithm. We navigate the complexities of managing severe cutaneous reactions in patients undergoing radiation. From identifying critical symptoms that necessitate urgent care to understanding the nuances of radiation dermatitis stages and risk factors, this episode is packed with expert insights and practical advice.  We focus on 2 specific areas:

1. Assessment and Severity Evaluation: Guidance on evaluating the severity of skin toxicities, incorporating case studies to illustrate practical approaches.
2. Management Protocols: Exploration of practical management strategies and specific interventions for common skin toxicities, drawing on literature evidence and expert consensus.

Learning Objectives:

Identify Critical Symptoms:

• Recognize severe cutaneous adverse reactions and understand when urgent care is necessary based on symptoms like fever, skin pain, blisters, mucous membrane involvement, and abnormal labs. 🚨

Understand Radiation Dermatitis:

• Differentiate between acute and chronic radiation dermatitis.
• Learn the grading systems (CTCAE and RTOG) and their simplified applications in the CASMO algorithm. 📊

How to Manage Radiation Dermatitis:

• Implement effective treatment strategies for both dry and moist desquamation.
• Understand the role of topical steroids and topical over-the-counter dos and don’ts💊

Recognize Risk Factors:

• Identify the factors that increase the risk of radiation dermatitis, considering the cancer type, radiation modality, and regimen. 🧬
• Learn to manage photosensitivity reactions, particularly with targeted therapies.
• Explore strategies to ensure patient adherence to prescribed skincare and sun protection protocols, emphasizing the importance of these measures in minimizing treatment interruptions. 🛡️

Photosensitivity Reactions:

• Understand the importance of proactive sun protection and the role of topical treatments. ☀️

Promote Adherence:

• Explore strategies to ensure patient adherence to prescribed skincare and sun protection protocols, emphasizing the importance of these measures in minimizing treatment interruptions. 🛡️

Episode Highlights:

• Danger Zone: Learn to identify those serious skin reactions that need urgent care, stat! 🌡️
• Radiation Dermatitis Deep Dive: Understand the stages and treatment of radiation dermatitis without getting lost in the weeds. 📋
• Risk Factors Unmasked: Get to know the usual suspects behind radiation dermatitis. 🔬
• Photosensitivity Savvy: Protect patients from those sneaky photosensitivity reactions with top-notch tips.  🌞
• Adherence Hacks: Keep patients sticking to their skincare and sun protection routines like glue.  🔄

Join us for a discussion perfect for a quick listen on your commute or work out🎧

REFERENCES AND FURTHER RESOURCES:

1.       The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2.       Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3.       Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4.       Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5.       Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6.       Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction (skintherapyletter.com)

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🌞🎧Dermatologist Dr.Max Sauder joins us and navigates us through the complexities of modern dermatological care💡

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 1🎙️

Get ready for a laugh and learn session as Dr. Jessica Asgarpour takes the co-hosting hot seat! This episode, we’re diving headfirst into the CASMO project with dermo-oncologist Dr. Max Sauder. We’ll decode the CASMO algorithm, tackle the nitty-gritty of managing skin toxicities, and even uncover Dr. Sauder's secret summer plans. Buckle up! 🎢

We're peeling back the layers of the CASMO project, an innovative approach to managing skin toxicities in cancer treatment. Can certain skin toxicities be prevented in patients? Is there a proactive skincare regimen that can be recommended?

1. Introduction to CaSMO and Skin Toxicities in Cancer Treatment: Overview of the significance of managing skin toxicities, introducing the CaSMO algorithm's development and objectives.
2. Prevention Strategies: Detailed discussion on general skincare measures recommended by CaSMO, including the rationale behind the use of cleansers and moisturizers to maintain skin hydration and integrity.

Episode Learning Objectives:

1. Understand the CASMO algorithm and its role in managing skin toxicities associated with cancer treatments.
2. Recognize the importance of a multidisciplinary approach in improving patient outcomes.
3. Identify practical proactive strategies for preventing and managing skin toxicities.
4. Learn about the impact of skin toxicities on patients' quality of life and how to address these issues.
5. Explore the role of various healthcare providers, including oncologists, nurses, and pharmacists, in supporting patients through their cancer journey.

Press play for a dose of dermatological delight 🎙️✨

Episode supported by an IME Grant from LA ROCHE POSAY

REFERENCES AND FURTHER RESOURCES:

1.       The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2.       Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3.       Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4.       Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5.       Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6.       Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction (skintherapyletter.com)

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🎙️ Melinda Knows Best at the AAD! 🌟

We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego! 

👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!

We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema. 

• Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Practical Tips for Dermatology Practices 🏥💼

• Adapting treatment plans for chronic hand eczema.
• Benefits of as-needed treatment approaches for better patient outcomes.

Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️

• Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫

Episode Learning Objectives:

1. Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
2. Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
3. Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments

Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫

🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍

Episode supported by an IME Grant from LEO Pharma

 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Dermatologist  |  Toronto 

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

References

1. Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

📻www.skinandjoints.ca

✉️[email protected]

🎙️🌞 Tight Spaces & Hair-Raising Breakthroughs – Live from AAD San Diego! 🎙️🌴

Join Skin and Joints Podcast AAD Guest Faculty and Vancouver based dermatologist, Dr,Diana Diao, as she navigates the cramped quarters of a historic boutique hotel in the Gaslamp Quarter—tiny rooms, weird noises, and all! 🏨😅

Dr. Diao explore groundbreaking sessions on alopecia areata, revealing innovative treatments and valuable clinical insights that are shaping the future of dermatology. 

 🌟💊Don't miss out on Dr. Diao's top clinical takeaways that could revolutionize treatment approaches for dermatologists everywhere. Whether it's systemic therapies for extensive scalp involvement or tailored treatments for unique patient profiles, this episode is packed with insights that promise to enhance patient care. 

💬 Tune in, transform your approach with pearls that could change your practice overnight! 

🎧✨ #SkinJointsPodcast #DermatologyInDepth

Learning Objectives:

1. Gain Insight into New Treatments for Alopecia Areata: Learn about the latest advancements and clinical trials discussed at AAD, including newly approved treatments and their application in real world practice.
2. Appreciate the Psychosocial Aspects of Dermatological Conditions: Recognize the significant emotional and social challenges faced by patients with alopecia areata and the importance of addressing these in real world practice.
3. Implement Clinical Pearls in Practice: Discover actionable tips and strategies that can be immediately applied to improve patient outcomes.

 #SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun 
Episode supported by an IME Grant from Pfizer and Bausch Health.

 

ABOUT DR.  DIANA DIAO FRCPC, FAAD

Dr. Diana Diao is a Dermatologist and a Clinical Instructor in the Department of Dermatology and Skin Science at the University of British Columbia. She is a consultant dermatologist at both Vancouver General Hospital and St. Paul’s Hospital. Dr. Diao practices medical and procedural dermatology, with a special interest in using energy-based modalities such as lasers to treat a variety of skin conditions.

Dr. Diao completed both her Medical Doctorate degree and dermatology residency training at the University of British Columbia, and is a Fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Diao is a mother, a published author, and has presented her work at conferences such as the World Congress of Dermatology and the American Academy of Dermatology meetings. Dr. Diao is also fluent in Mandarin.

📻www.skinandjoints.ca

✉️[email protected]

🎙️🌞 An AAD 2024 Coles Notes Deep Dive – Welcome to a potpourri episode of the Skin and Joints Podcast, streaming from the vibrant city of San Diego. 

Join us as we sit down with Guest Faculty dermatologist expert the much-anticipated Dr. Mark Kirchhoff, whose voice is as deep and profound as his insights into dermatology. 🎤💬

Medical Innovations Uncovered:

• Key Sessions from AAD: We traverse the entire meeting with key insights into s🎙️🌞 An AAD 2024 Coles Notes Deep Dive – Welcome to a potpourri episode of the Skin and Joints Podcast, streaming from the vibrant city of San Diego. 

Join us as we sit down with Guest Faculty dermatologist expert the much-anticipated Dr. Mark Kirchhoff, whose voice is as deep and profound as his insights into dermatology. 🎤💬

Medical Innovations Uncovered:

• Key Sessions from AAD: We traverse the entire meeting with key insights into significant advancements, focusing on HS, AD, PsO and AA.

• Late Breaker Highlights: An overview of the most cutting-edge studies presented, including potential new therapies and their implications for future treatment protocols including rethinking long term disease remission to the exploration of new and novel therapeutic targets.

Learning Objectives:

• Delve into Dermatological Innovations: Get the latest updates on groundbreaking treatments for HS, AA, AD and PsO as well as other skin conditions from the AAD meeting. 🔬💡
• Discuss Future Directions in Dermatology: Examine the potential shifts in treatment approaches and how they align with current patient needs and future therapeutic strategies. 🌟

Dr. Kirchhoff also reflects on the changing landscape of medical conferences influenced by social media and digital dissemination of knowledge

Join us for a blend of professional insights and personal anecdotes that promise to educate and entertain. Tune in to catch Dr. Kirchhoff’s voice and vision for the future of dermatology! 📚🎧

 #SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun 

Episode supported by an IME Grant from Pfizer and Bausch Health.

 

ABOUT DR. MARK KIRCHHOF,MD, PHD, FRCPC, FAAD

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 40 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.ignificant advancements, focusing on HS, AD, PsO and AA.

• Late Breaker Highlights: An overview of the most cutting-edge studies presented, including potential new therapies and their implications for future treatment protocols including rethinking long term disease remission to the exploration of new and novel therapeutic targets.

Learning Objectives:

• Delve into Dermatological Innovations: Get the latest updates on groundbreaking treatments for HS, AA, AD and PsO as well as other skin conditions from the AAD meeting. 🔬💡
• Discuss Future Directions in Dermatology: Examine the potential shifts in treatment approaches and how they align with current patient needs and future therapeutic strategies. 🌟

Dr. Kirchhoff also reflects on the changing landscape of medical conferences influenced by social media and digital dissemination of knowledge

Join us for a blend of professional insights and personal anecdotes that promise to educate and entertain. Tune in to catch Dr. Kirchhoff’s voice and vision for the future of dermatology! 📚🎧

 #SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun 

Episode supported by an IME Grant from Pfizer and Bausch Health.

 

ABOUT DR. MARK KIRCHHOF,MD, PHD, FRCPC, FAAD

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 40 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.

📻www.skinandjoints.ca

✉️[email protected]